More Articles

AAM Annual Meeting – Access! 2020 Conferences | Posted 07/02/2020

AAM Annual Meeting – Access! 2020 11–13 May 2020 Washington, DCUSA

Top 10 most read GaBI Online articles in 2019 Pharma News | Posted 31/01/2020

It has once again been a busy year for biosimilars. One of the most important milestones for biosimilars in 2019 was the World Health Organization (WHO) pilot programme to prequalify rituximab and...

Law and ethics of switching to biosimilars in Canada Biosimilars/Research | Posted 31/01/2020

With healthcare budgets in mind, governments and financial institutions across the globe are planning or implementing non-medical or ‘forced’ switches by cutting drug coverage for reference biologi...

Biosimilars applications under review by EMA – January 2020 Biosimilars/General | Posted 31/01/2020

The European Medicines Agency (EMA) is the body responsible for approval of biosimilars within the European Union (EU). A legal framework for approving biosimilars was established in 2003. Approval...

Mabpharm files infliximab copy biological application in China Biosimilars/News | Posted 31/01/2020

US-based biopharmaceutical company Sorrento Therapeutics (Sorrento) announced on 6 January 2020 that its partner, China-based Mabpharm, had filed a marketing application with China’s National Medic...

Adalimumab biosimilars in Europe: a review Biosimilars/Research | Posted 31/01/2020

A recent position statement from the Belgian inflammatory bowel disease (IBD) research group (BIRD) reviews the five biosimilars of adalimumab available in the European Union (EU) [1]. Adalimumab,...

Chemically synthesized polypeptides to use biosimilars pathway Policies & Legislation | Posted 31/01/2020

The US Food and Drug Administration (FDA) is supporting a change in the government spending bill that will allow for chemically synthesized polypeptides to also be classified as biologicals.

China approves bevacizumab copy biological Ankada Biosimilars/News | Posted 31/01/2020

China’s National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), announced on 9 December 2019 that it had approved Ankada, a bevacizumab copy biologi...